8:23am Integrative Health in Radiation Oncology – Heather Zinkin, MD

Winther, K., Rein, E., & Hedman, C. (2005). Femal, a herbal remedy made from pollen extracts, reduces hot flushes and improves quality of life in menopausal women: a randomized, placebo-controlled, parallel study. Climacteric : the journal of the International Menopause Society, 8(2), 162–170. https://doi.org/10.1080/13697130500117987

Thomson, C. A., Rock, C. L., Thompson, P. A., Caan, B. J., Cussler, E., Flatt, S. W., & Pierce, J. P. (2011). Vegetable intake is associated with reduced breast cancer recurrence in tamoxifen users: a secondary analysis from the Women’s Healthy Eating and Living Study. Breast cancer research and treatment, 125(2), 519–527. https://doi.org/10.1007/s10549-010-1014-9

Chlebowski, R. T., Aragaki, A. K., Anderson, G. L., Simon, M. S., Manson, J. E., Neuhouser, M. L., Pan, K., Stefanic, M. L., Rohan, T. E., Lane, D., Qi, L., Snetselaar, L., & Prentice, R. L. (2018). Association of Low-Fat Dietary Pattern With Breast Cancer Overall Survival: A Secondary Analysis of the Women’s Health Initiative Randomized Clinical Trial. JAMA oncology, 4(10), e181212. https://doi.org/10.1001/jamaoncol.2018.1212

Taylor, E. F., Burley, V. J., Greenwood, D. C., & Cade, J. E. (2007). Meat consumption and risk of breast cancer in the UK Women’s Cohort Study. British journal of cancer, 96(7), 1139–1146. https://doi.org/10.1038/sj.bjc.6603689)

Thiébaut, A. C., Jiao, L., Silverman, D. T., Cross, A. J., Thompson, F. E., Subar, A. F., Hollenbeck, A. R., Schatzkin, A., & Stolzenberg-Solomon, R. Z. (2009). Dietary fatty acids and pancreatic cancer in the NIH-AARP diet and health study. Journal of the National Cancer Institute, 101(14), 1001–1011. https://doi.org/10.1093/jnci/djp168

Rodrigues Dos Santos, C., Fonseca, I., Dias, S., & Mendes de Almeida, J. C. (2014). Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression. BMC cancer, 14, 132. https://doi.org/10.1186/1471-2407-14-132

Sakellakis, M., Akinosoglou, K., Kostaki, A., Spyropoulou, D., & Koutras, A. (2016). Statins and risk of breast cancer recurrence. Breast cancer (Dove Medical Press), 8, 199–205. https://doi.org/10.2147/BCTT.S116694

Gong, T. T., Li, D., Wu, Q. J., & Wang, Y. Z. (2016). Cholesterol consumption and risk of endometrial cancer: a systematic review and dose-response meta-analysis of observational studies. Oncotarget, 7(13), 16996–17008. https://doi.org/10.18632/oncotarget.7913

García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020). Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. Biomolecules, 10(11), 1575. https://doi.org/10.3390/biom10111575

Fisher, E., Moore, R. A., Fogarty, A. E., Finn, D. P., Finnerup, N. B., Gilron, I., Haroutounian, S., Krane, E., Rice, A., Rowbotham, M., Wallace, M., & Eccleston, C. (2021). Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain, 162(Suppl 1), S45–S66. https://doi.org/10.1097/j.pain.0000000000001929

9am Management of Lymphoma in the PET Era – Yolanda Tseng, MD

Fuchs, M., Goergen, H., Kobe, C., Kuhnert, G., Lohri, A., Greil, R., Sasse, S., Topp, M. S., Schäfer, E., Hertenstein, B., Soekler, M., Vogelhuber, M., Zijlstra, J. M., Keller, U. B., Krause, S. W., Wilhelm, M., Maschmeyer, G., Thiemer, J., Dührsen, U., Meissner, J., … Engert, A. (2019). Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37(31), 2835–2845. https://doi.org/10.1200/JCO.19.00964

André, M., Girinsky, T., Federico, M., Reman, O., Fortpied, C., Gotti, M., Casasnovas, O., Brice, P., van der Maazen, R., Re, A., Edeline, V., Fermé, C., van Imhoff, G., Merli, F., Bouabdallah, R., Sebban, C., Specht, L., Stamatoullas, A., Delarue, R., Fiaccadori, V., … Raemaekers, J. (2017). Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35(16), 1786–1794. https://doi.org/10.1200/JCO.2016.68.6394

Radford, J., Illidge, T., Counsell, N., Hancock, B., Pettengell, R., Johnson, P., Wimperis, J., Culligan, D., Popova, B., Smith, P., McMillan, A., Brownell, A., Kruger, A., Lister, A., Hoskin, P., O’Doherty, M., & Barrington, S. (2015). Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. The New England journal of medicine, 372(17), 1598–1607. https://doi.org/10.1056/NEJMoa1408648

Borchmann, P., Plütschow, A., Kobe, C., Greil, R., Meissner, J., Topp, M. S., Ostermann, H., Dierlamm, J., Mohm, J., Thiemer, J., Sökler, M., Kerkhoff, A., Ahlborn, M., Halbsguth, T. V., Martin, S., Keller, U., Balabanov, S., Pabst, T., Vogelhuber, M., Hüttmann, A., … Engert, A. (2021). PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology, 22(2), 223–234. https://doi.org/10.1016/S1470-2045(20)30601-X

Sehn, L. H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., Klasa, R., Savage, K. J., Shenkier, T., Sutherland, J., Gascoyne, R. D., & Connors, J. M. (2007). The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109(5), 1857–1861. https://doi.org/10.1182/blood-2006-08-038257

9:23am Updates in Head and Neck – Sewit Teckie, MD

Nichols, A. C., Lang, P., Prisman, E., Berthelet, E., Tran, E., Hamilton, S., Wu, J., Fung, K., de Almeida, J. R., Bayley, A., Goldstein, D. P., Eskander, A., Husain, Z., Bahig, H., Christopoulous, A., Hier, M., Sultanem, K., Richardson, K., Mlynarek, A., Krishnan, S., … Palma, D. A. (2020). Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): study protocol for a randomized phase II trial. BMC cancer, 20(1), 125. https://doi.org/10.1186/s12885-020-6607-z

Yom, S. S., Torres-Saavedra, P., Caudell, J. J., Waldron, J. N., Gillison, M. L., Xia, P., Truong, M. T., Kong, C., Jordan, R., Subramaniam, R. M., Yao, M., Chung, C. H., Geiger, J. L., Chan, J. W., O’Sullivan, B., Blakaj, D. M., Mell, L. K., Thorstad, W. L., Jones, C. U., Banerjee, R. N., … Le, Q. T. (2021). Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(9), 956–965. https://doi.org/10.1200/JCO.20.03128

10:30am Current Approach to Management of Spinal Metastases – Kristin Redmond, MD

Sahgal, A., Myrehaug, S. D., Siva, S., Masucci, G. L., Maralani, P. J., Brundage, M., Butler, J., Chow, E., Fehlings, M. G., Foote, M., Gabos, Z., Greenspoon, J., Kerba, M., Lee, Y., Liu, M., Liu, S. K., Thibault, I., Wong, R. K., Hum, M., Ding, K., … trial investigators (2021). Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial. The Lancet. Oncology, 22(7), 1023–1033. https://doi.org/10.1016/S1470-2045(21)00196-0

Sahgal, A., Atenafu, E. G., Chao, S., Al-Omair, A., Boehling, N., Balagamwala, E. H., Cunha, M., Thibault, I., Angelov, L., Brown, P., Suh, J., Rhines, L. D., Fehlings, M. G., & Chang, E. (2013). Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(27), 3426–3431. https://doi.org/10.1200/JCO.2013.50.1411

Mizumoto, M., Harada, H., Asakura, H., Hashimoto, T., Furutani, K., Hashii, H., Murata, H., Takagi, T., Katagiri, H., Takahashi, M., & Nishimura, T. (2011). Radiotherapy for patients with metastases to the spinal column: a review of 603 patients at Shizuoka Cancer Center Hospital. International journal of radiation oncology, biology, physics, 79(1), 208–213. https://doi.org/10.1016/j.ijrobp.2009.10.056

10:53am Updates in CNS Oncology – John Suh, MD

Redmond, K. J., Robertson, S., Lo, S. S., Soltys, S. G., Ryu, S., McNutt, T., Chao, S. T., Yamada, Y., Ghia, A., Chang, E. L., Sheehan, J., & Sahgal, A. (2017). Consensus Contouring Guidelines for Postoperative Stereotactic Body Radiation Therapy for Metastatic Solid Tumor Malignancies to the Spine. International journal of radiation oncology, biology, physics, 97(1), 64–74. https://doi.org/10.1016/j.ijrobp.2016.09.014

Iheagwara UK, Siddiqui Z, Holeva K, et al. A phase II study to determine the efficacy of preoperative stereotactic radiosurgery followed by resection of brain metastases. Int J Radiat Oncol Biol Phys 111(3S):S25-26, 2021. DOI: https://doi.org/10.1016/j.ijrobp.2021.07.086

Tom Mc, DiFilippo F, Smile T, et al. 18F fluciclovine PET/CT to distinguish radiation necrosis from tumor progression in brain metastases treated with stereotactic radiosurgery: results of a prospective pilot study.  Int J Radiat Oncol Biol Phys 111(3S):S27, 2021. https://doi.org/10.1016/j.ijrobp.2021.07.089

11:30am Updates in GU Malignancies – Seth Blacksburg, MD

Tree A, Proceedings of European Society Radiation Oncology (ESTRO), 2021. https://www.estro.org/Congresses/ESTRO-2021

Brand, D. H., Tree, A. C., Ostler, P., van der Voet, H., Loblaw, A., Chu, W., Ford, D., Tolan, S., Jain, S., Martin, A., Staffurth, J., Camilleri, P., Kancherla, K., Frew, J., Chan, A., Dayes, I. S., Henderson, D., Brown, S., Cruickshank, C., Burnett, S., … PACE Trial Investigators (2019). Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. The Lancet. Oncology, 20(11), 1531–1543. https://doi.org/10.1016/S1470-2045(19)30569-8

Krauss D, et al., Proceedings of the American Society for Therapeutic Radiation Oncology, Plenary Session; 2021.  https://www.astro.org/Meetings-and-Education/Micro-Sites/2021/Annual-Meeting

Phillips, R., Shi, W. Y., Deek, M., Radwan, N., Lim, S. J., Antonarakis, E. S., Rowe, S. P., Ross, A. E., Gorin, M. A., Deville, C., Greco, S. C., Wang, H., Denmeade, S. R., Paller, C. J., Dipasquale, S., Deweese, T. L., Song, D. Y., Wang, H., Carducci, M. A., … Tran, P. T. (2020). Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncology, 6(5), 650-659. https://doi.org/10.1001/jamaoncol.2020.014

11:53am The Radiopharmaceutical Explosion in Radiation Oncology – Michael R. Folkert, MD, PhD, DABR

Parker C et al “Alpha emitter radium-223 and survival in metastatic prostate cancer,” N Engl J Med. 369(3):213-23 (2013). https://www.nejm.org/doi/pdf/10.1056/NEJMoa1213755

Sartor, O., Coleman, R., Nilsson, S., Heinrich, D., Helle, S. I., O’Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Widmark, A., Johannessen, D. C., Hoskin, P., James, N. D., Solberg, A., Syndikus, I., Vogelzang, N. J., O’Bryan-Tear, C. G., Shan, M., Bruland, Ø. S., … Parker, C. (2014). Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. The Lancet. Oncology, 15(7), 738–746. https://doi.org/10.1016/S1470-2045(14)70183-4

Imhof, A., Brunner, P., Marincek, N., Briel, M., Schindler, C., Rasch, H., Mäcke, H. R., Rochlitz, C., Müller-Brand, J., & Walter, M. A. (2011). Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(17), 2416–2423. https://doi.org/10.1200/JCO.2010.33.7873

Hurwitz, M., Buscombe, J. R., Jacene, H. A., Klitzke, A. K., Lamonica, D., Lu, Y., Pryma, D. A., Rohren, E. M., Speer, T. W., Subramaniam, R. M., Thompson, H. M., Tomblyn, M. B., Wong, W. W., Xiao, Y., Banks, K. P., & Brown, R. (2020). ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223. American journal of clinical oncology, 43(8), 539–544. https://doi.org/10.1097/COC.0000000000000702

Kennedy A. (2014). Radioembolization of hepatic tumors. Journal of gastrointestinal oncology, 5(3), 178–189. https://doi.org/10.3978/j.issn.2078-6891.2014.037

Elsayed, M., Martin, J. G., Dabrowiecki, A., Goldman, D. T., Faraj, R., McMahon, J. T., Kokabi, N., Duszak, R., Jr, Newsome, J., & Bercu, Z. L. (2019). Tc-99m-MAA lung shunt fraction before Y-90 radioembolization is low among patients with non-hepatocellular carcinoma malignancies. Nuclear medicine communications, 40(11), 1154–1157. https://doi.org/10.1097/MNM.0000000000001089

Hofman M et al , “[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial,” Lancet 397(10276):797-804 (2021)  https://doi.org/10.1016/S0140-6736(21)00237-3

Fendler, W. P., Rahbar, K., Herrmann, K., Kratochwil, C., & Eiber, M. (2017). 177Lu-PSMA radioligand therapy for prostate cancer. Journal of Nuclear Medicine, 58(8), 1196-1200. https://scholar.google.com/scholar?q=177Lu-PSMA+Radioligand+Therapy+for+Prostate+Cancer&hl=en&as_sdt=0&as_vis=1&oi=scholart

Sartor O, et al, “Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer,” N Engl J Med 385:1091-1103 (2021). https://www.nejm.org/doi/full/10.1056/nejmoa2107322#article_citing_articles

1pm Updates in Breast Oncology – Rachel Jimenez, MD

Murray Brunt, A., Haviland, J. S., Wheatley, D. A., Sydenham, M. A., Alhasso, A., Bloomfield, D. J., Chan, C., Churn, M., Cleator, S., Coles, C. E., Goodman, A., Harnett, A., Hopwood, P., Kirby, A. M., Kirwan, C. C., Morris, C., Nabi, Z., Sawyer, E., Somaiah, N., Stones, L., … FAST-Forward Trial Management Group (2020). Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet (London, England), 395(10237), 1613–1626. https://doi.org/10.1016/S0140-6736(20)30932-6

Kim, Y. B., Byun, H. K., Kim, D. Y., Ahn, S. J., Lee, H. S., Park, W., Kim, S. S., Kim, J. H., Lee, K. C., Lee, I. J., Kim, W. T., Shin, H. S., Kim, K., Shin, K. H., Nam, C. M., & Suh, C. O. (2021). Effect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women With Node-Positive Breast Cancer: A Randomized Phase 3 Clinical Trial. JAMA oncology, e216036. Advance online publication. https://doi.org/10.1001/jamaoncol.2021.6036

Chmura, S., Winter, K. A., Robinson, C., Pisansky, T. M., Borges, V., Al-Hallaq, H., Matuszak, M., Park, S. S., Yi, S., Hasan, Y., Bazan, J., Wong, P., Yoon, H. A., Horton, J., Gan, G., Milano, M. T., Sigurdson, E. R., Moughan, J., Salama, J. K., & White, J. (2021). Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial. JAMA oncology, 7(6), 845–852. https://doi.org/10.1001/jamaoncol.2021.0687

1:23pm Updates in Thoracic Oncology – Joe Y. Chang, MD

Ball, D., Mai, G. T., Vinod, S., Babington, S., Ruben, J., Kron, T., Chesson, B., Herschtal, A., Vanevski, M., Rezo, A., Elder, C., Skala, M., Wirth, A., Wheeler, G., Lim, A., Shaw, M., Schofield, P., Irving, L., Solomon, B., & TROG 09.02 CHISEL investigators (2019). Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. The Lancet. Oncology, 20(4), 494–503. https://doi.org/10.1016/S1470-2045(18)30896-9

Chang, J. Y., Senan, S., Paul, M. A., Mehran, R. J., Louie, A. V., Balter, P., Groen, H. J., McRae, S. E., Widder, J., Feng, L., van den Borne, B. E., Munsell, M. F., Hurkmans, C., Berry, D. A., van Werkhoven, E., Kresl, J. J., Dingemans, A. M., Dawood, O., Haasbeek, C. J., Carpenter, L. S., … Roth, J. A. (2015). Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. The Lancet. Oncology, 16(6), 630–637. https://doi.org/10.1016/S1470-2045(15)70168-3

Brooks, E. D., Sun, B., Feng, L., Verma, V., Zhao, L., Gomez, D. R., Liao, Z., Jeter, M., O’Reilly, M., Welsh, J. W., Nguyen, Q. N., Erasmus, J. J., Eapen, G., Ahrar, K., Antonoff, M. B., Hahn, S. M., Heymach, J. V., Rice, D. C., & Chang, J. Y. (2018). Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. JAMA network open, 1(4), e181390. https://doi.org/10.1001/jamanetworkopen.2018.1390

Chang, J. Y., Bezjak, A., Mornex, F., & IASLC Advanced Radiation Technology Committee (2015). Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 10(4), 577–585. https://doi.org/10.1097/JTO.0000000000000453

Zhao, L., Zhou, S., Balter, P., Shen, C., Gomez, D. R., Welsh, J. D., Lin, S. H., & Chang, J. Y. (2016). Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy. International journal of radiation oncology, biology, physics, 95(4), 1226–1235. https://doi.org/10.1016/j.ijrobp.2016.01.065

Morenno et al:  JTO 15:101, 2020  https://www.jto.org/article/S1556-0864(19)33191-0/fulltext

2pm Updates in GYN – Kaled Alektiar, MD

León-Castillo, A., de Boer, S. M., Powell, M. E., Mileshkin, L. R., Mackay, H. J., Leary, A., Nijman, H. W., Singh, N., Pollock, P. M., Bessette, P., Fyles, A., Haie-Meder, C., Smit, V., Edmondson, R. J., Putter, H., Kitchener, H. C., Crosbie, E. J., de Bruyn, M., Nout, R. A., Horeweg, N., … TransPORTEC consortium (2020). Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(29), 3388–3397. https://doi.org/10.1200/JCO.20.00549

Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)

Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculation. New York Society of Nuclear Medicine, 1988.   https://www.osti.gov/servlets/purl/5915860

Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., Akabani, G., SNM MIRD Committee, Bolch, W. E., Brill, A. B., Fisher, D. R., Howell, R. W., Meredith, R. F., Sgouros, G., Wessels, B. W., & Zanzonico, P. B. (2010). MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 51(2), 311–328. https://doi.org/10.2967/jnumed.108.058651

Hobbs, R. F., McNutt, T., Baechler, S., He, B., Esaias, C. E., Frey, E. C., Loeb, D. M., Wahl, R. L., Shokek, O., & Sgouros, G. (2011). A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy. International journal of radiation oncology, biology, physics, 80(4), 1256–1262. https://doi.org/10.1016/j.ijrobp.2010.08.022

2:23pm Updates in GI Tumors – Karyn Goodman, MD, MS

Hulshof M, Geijsen ED, Rozema T, et al. Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study). J Clin Oncol. 2021;39(25):2816-2824. https://ascopubs.org/doi/abs/10.1200/JCO.20.03697

Goodman, K. A., Ou, F. S., Hall, N. C., Bekaii-Saab, T., Fruth, B., Twohy, E., Meyers, M. O., Boffa, D. J., Mitchell, K., Frankel, W. L., Niedzwiecki, D., Noonan, A., Janjigian, Y. Y., Thurmes, P. J., Venook, A. P., Meyerhardt, J. A., O’Reilly, E. M., & Ilson, D. H. (2021). Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(25), 2803–2815. https://doi.org/10.1200/JCO.20.03611

De Felice, F., Tombolini, V., & Cortesi, E. (2021). Total neoadjuvant treatment in locally advanced rectal cancer. Translational oncology, 14(5), 101044. https://doi.org/10.1016/j.tranon.2021.101044

Physics Track

10:20 am Updates in Physics – Jenghwa Chang, PhD

Jagsi, R., Bekelman, J. E., Chen, A., Chen, R. C., Hoffman, K., Shih, Y. C., Smith, B. D., & Yu, J. B. (2014). Considerations for observational research using large data sets in radiation oncology. International journal of radiation oncology, biology, physics, 90(1), 11–24. https://doi.org/10.1016/j.ijrobp.2014.05.013

Daguenet E, Louati S, Wozny AS, Vial N, Gras M, Guy JB, Vallard A, Rodriguez-Lafrasse C, Magné N. Radiation-induced bystander and abscopal effects: important lessons from preclinical models. Br J Cancer 2020;123:339-348.10.1038/s41416-020-0942-3. https://www.nature.com/articles/s41416-020-0942-3

Wu, X., Perez, N. C., Zheng, Y., Li, X., Jiang, L., Amendola, B. E., Xu, B., Mayr, N. A., Lu, J. J., Hatoum, G. F., Zhang, H., Chang, S. X., Griffin, R. J., & Guha, C. (2020). The Technical and Clinical Implementation of LATTICE Radiation Therapy (LRT). Radiation research, 194(6), 737–746. https://doi.org/10.1667/RADE-20-00066.1

Rahman, M., Ashraf, M. R., Zhang, R., Bruza, P., Dexter, C. A., Thompson, L., Cao, X., Williams, B. B., Hoopes, P. J., Pogue, B. W., & Gladstone, D. J. (2021). Electron FLASH Delivery at Treatment Room Isocenter for Efficient Reversible Conversion of a Clinical LINAC. International journal of radiation oncology, biology, physics, 110(3), 872–882. https://doi.org/10.1016/j.ijrobp.2021.01.011

10:50 am  Automated Treatment Planning – Linda X. Hong, PhD

Kevin L. Moore. Automated Radiotherapy Treatment Planning. Semin Radiat Oncol 2019, 29:209−218. https://doi.org/10.1016/j.semradonc.2019.02.003

Mohammad Hussein, Ben J M Heijmen, Dirk Verellen and Andrew Nisbet, Automation in intensity modulated radiotherapy treatment planning—a review of recent innovations. Br J Radiol 2018; 91: 20180270. https://doi.org/10.1259/bjr.20180270

11:20 am Radiopharmaceutical dosimetry and treatment planning – Robert F. Hobbs, PhD

Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., Akabani, G., SNM MIRD Committee, Bolch, W. E., Brill, A. B., Fisher, D. R., Howell, R. W., Meredith, R. F., Sgouros, G., Wessels, B. W., & Zanzonico, P. B. (2010). MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 51(2), 311–328. https://doi.org/10.2967/jnumed.108.058651

Hobbs, R. F., McNutt, T., Baechler, S., He, B., Esaias, C. E., Frey, E. C., Loeb, D. M., Wahl, R. L., Shokek, O., & Sgouros, G. (2011). A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy. International journal of radiation oncology, biology, physics, 80(4), 1256–1262. https://doi.org/10.1016/j.ijrobp.2010.08.022

11:50 pm Panel Discussion: Challenges of Implementing radiopharmaceutical therapy (RPT)

Moderator: John Humm, PhD

Panelists: Rachel M. Bartlett, PhD, DABR; Yijian Cao, PhD; Daniel J. Samson, CHP

Luca Filippi a, et al, EXPERT REVIEW OF MEDICAL DEVICES2020, VOL. 17, NO. 4, 331–343 https://doi.org/10.1080/17434440.2020.1741348

Coleman, R., Aksnes, A. K., Naume, B., Garcia, C., Jerusalem, G., Piccart, M., Vobecky, N., Thuresson, M., & Flamen, P. (2014). A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast cancer research and treatment, 145(2), 411–418. https://doi.org/10.1007/s10549-014-2939-1

Theranostic approaches in nuclear medicine: current status and future prospects Luca Filippi a, et al, EXPERT REVIEW OF MEDICAL DEVICES2020, VOL. 17, NO. 4, 331–343 https://doi.org/10.1080/17434440.2020.1741348